Chemical activators of SFTPG can engage distinct cellular signaling pathways to enhance its activity. Forskolin and Rolipram both raise intracellular cAMP levels, which activates protein kinase A (PKA). PKA then phosphorylates target proteins, and this phosphorylation can lead to the activation of SFTPG. Similarly, IBMX acts to increase cAMP by inhibiting phosphodiesterases which break down cAMP, thereby sustaining the activation signal for longer periods. Zaprinast follows a parallel route by inhibiting PDE5, thus increasing cGMP levels, which can activate protein kinase G (PKG). PKG, like PKA, phosphorylates serine and threonine residues on target proteins, providing a mechanism for the activation of SFTPG.
Phorbol 12-myristate 13-acetate (PMA) directly stimulates protein kinase C (PKC), which is known to phosphorylate a wide array of proteins, and this can result in the phosphorylation and activation of SFTPG. Ionomycin, by increasing intracellular calcium levels, can activate calmodulin-dependent protein kinases (CaMK), which again could lead to the phosphorylation and activation of SFTPG. Phosphatidic Acid, through its role as a second messenger, activates mammalian target of rapamycin (mTOR), which can initiate signaling cascades resulting in the phosphorylation of target proteins, thus potentially activating SFTPG. FTY720, by activating sphingosine-1-phosphate receptors, can initiate signaling cascades involving PKC, which could then phosphorylate and activate SFTPG. Additionally, Okadaic Acid and Calyculin A prevent the dephosphorylation of proteins by inhibiting protein phosphatases PP1 and PP2A, which could result in a sustained activation state of SFTPG. Finally, Anisomycin activates the stress-activated protein kinases (SAPKs), which can target and phosphorylate SFTPG, leading to its activation. Each of these chemicals activates SFTPG via a targeted phosphorylation mechanism, ensuring the protein's functional enhancement without merely increasing its expression or general protein translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylyl cyclase increasing cAMP levels, which can enhance the activation of SFTPG via PKA. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Inhibits phosphodiesterases, increasing cAMP levels and potentially enhancing SFTPG activation via PKA. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Directly activates PKC which could lead to the phosphorylation and activation of SFTPG. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular Ca²⁺, potentially activating CaMK which could phosphorylate and activate SFTPG. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Inhibits PP1 and PP2A, preventing dephosphorylation and potentially maintaining SFTPG in an active state. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Activates SAPKs which can phosphorylate and activate SFTPG. | ||||||
Phosphatidic Acid, Dipalmitoyl | 169051-60-9 | sc-201057 sc-201057B sc-201057A | 100 mg 250 mg 500 mg | $104.00 $239.00 $409.00 | ||
Activates mTOR, which could lead to SFTPG activation through downstream kinase phosphorylation. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
Activates S1P receptors that could lead to PKC activation and subsequent SFTPG phosphorylation. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
Directly activates PKA, which can phosphorylate and activate SFTPG. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Inhibits PDE5 increasing cGMP levels, which can activate PKG leading to the activation of SFTPG. | ||||||